Ila M. Harris
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ila M. Harris has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Alex S. Carmon
American College of Clinical Pharmacy
1 shared publicationAnn M. Philbrick
1 shared publication- Ann M. Philbrick
Associate Professor. Department of Pharmaceutical Care and Health Systems. University of Minnesota College of Pharmacy. Minneapolis, MN
1 shared publication - Faria Munir
University of Illinois Chicago Retzky College of Pharmacy Chicago Illinois USA
1 shared publication - Karen L. Kier
College of Pharmacy Ohio Northern University Ada Ohio USA
1 shared publication - Kristen C. Klemenhagen
Department of Family Medicine and Community Health University of Minnesota Medical School Twin Cities Minneapolis Minnesota USA
1 shared publication
Latest Publications
- Open Access
- 11 September 2026
- Published by Elsevier in Kidney Medicine
- Vol. 8 (11)
Drug Dosing in Chronic Kidney Disease: Comparison of Standardized eGFR and eGFR Adjusted for Body Surface Area
- 11 September 2026
- Published by Elsevier in Kidney Medicine
- Vol. 8 (11)
Open AccessDrug Dosing in Chronic Kidney Disease: Comparison of Standardized eGFR and eGFR Adjusted for Body Surface Area
- Open Access
- 3 July 2024
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 7 (9) , 947-951
Pharmacists' role in combating medical misinformation
Medical misinformation can pose serious threats to public health. This commentary explores the pharmacist's unique role in addressing and mitigating the impact of medical misinformation. Pharmacists are uniquely positioned to engage with other healthcare providers, patients, and communities to dispel myths, provide accurate information, and promote evidence‐based healthcare decision‐making. This commentary showcases examples of the multifaceted roles of pharmacists in combating medical misinformation. It explores various strategies and interventions that can be used by pharmacists, including patient education, effective communication, information dissemination, and community engagement. Pharmacists' interventions are often at the intersection of medication management and health information needs, making them integral in ensuring patients and providers make informed healthcare choices. Moreover, this commentary highlights the impact pharmacists can have as advocates for scientific rigor and evidence‐based practices within healthcare systems to educate against medical misinformation and discusses the need for continued education, training, and support for pharmacists to excel in their roles as healthcare educators and medication experts. Pharmacists have a role in countering medical misinformation when serving patients by providing information that empowers a more informed society.
- 3 July 2024
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 7 (9) , 947-951
Open AccessPharmacists' role in combating medical misinformation
Medical misinformation can pose serious threats to public health. This commentary explores the pharmacist's unique role in addressing and mitigating the impact of medical misinformation. Pharmacists are uniquely positioned to engage with other healthcare providers, patients, and communities to dispel myths, provide accurate information, and promote evidence‐based healthcare decision‐making. This commentary showcases examples of the multifaceted roles of pharmacists in combating medical misinformation. It explores various strategies and interventions that can be used by pharmacists, including patient education, effective communication, information dissemination, and community engagement. Pharmacists' interventions are often at the intersection of medication management and health information needs, making them integral in ensuring patients and providers make informed healthcare choices. Moreover, this commentary highlights the impact pharmacists can have as advocates for scientific rigor and evidence‐based practices within healthcare systems to educate against medical misinformation and discusses the need for continued education, training, and support for pharmacists to excel in their roles as healthcare educators and medication experts. Pharmacists have a role in countering medical misinformation when serving patients by providing information that empowers a more informed society.
- Open Access
- 14 January 2024
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 7 (3) , 215-223
Evaluation of single maintenance and reliever therapy (SMART) prescribing of budesonide‐formoterol for asthma after a clinical pharmacist‐led initiative
Introduction: Single maintenance and reliever therapy (SMART) with a combination inhaled corticosteroid‐formoterol inhaler is the preferred asthma treatment by the Global Initiative for Asthma and the National Asthma Education and Prevention Program guidelines. These recommendations have been slow to be implemented routinely into clinical practice.Methods: This was an observational cohort study conducted in a family medicine residency program clinic. A clinical pharmacist‐led initiative to implement SMART, which included provider education and the development of clinical tools to facilitate SMART prescribing, was assessed. Year 1 (Y1; pre‐intervention) and year 2 (Y2; post‐intervention) were compared.Outcomes: The primary outcome was to evaluate the impact of this initiative on the frequency of SMART (budesonide‐formoterol without albuterol) prescribing. Prescription frequencies for albuterol and budesonide‐formoterol were also compared separately. Secondary outcomes were Asthma Control Test (ACT) scores and prescribing frequencies among faculty and resident physicians.Results: The total number of eligible patients in the clinic population was 807, and 459 of these patients met the inclusion criteria. There were more females than males, and the mean age was 39. About 24% had a language preference other than English and 22% required an interpreter. The percentage of patients who were prescribed SMART significantly increased from 0.44% to 11.5% (p < 0.001). Budesonide‐formoterol prescriptions increased from 7.4% to 34.6% (p < 0.001). Albuterol metered‐dose inhaler prescriptions decreased from 79.7% to 66.2% (p < 0.001). Prescribing patterns were similar for patients of faculty physicians (n = 258) and resident physicians (n = 196). Only 164 (35.7%) patients had an ACT score in Y1 and Y2, and the mean ACT score was not significantly different between Y1 and Y2 (p = 0.973).Conclusion: A clinical pharmacist‐led SMART asthma prescribing initiative was associated with a significant increase in SMART prescribing, a significant increase in budesonide‐formoterol prescribing, and a significant decrease in albuterol prescribing.
- 14 January 2024
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 7 (3) , 215-223
Open AccessEvaluation of single maintenance and reliever therapy (SMART) prescribing of budesonide‐formoterol for asthma after a clinical pharmacist‐led initiative
Introduction: Single maintenance and reliever therapy (SMART) with a combination inhaled corticosteroid‐formoterol inhaler is the preferred asthma treatment by the Global Initiative for Asthma and the National Asthma Education and Prevention Program guidelines. These recommendations have been slow to be implemented routinely into clinical practice.Methods: This was an observational cohort study conducted in a family medicine residency program clinic. A clinical pharmacist‐led initiative to implement SMART, which included provider education and the development of clinical tools to facilitate SMART prescribing, was assessed. Year 1 (Y1; pre‐intervention) and year 2 (Y2; post‐intervention) were compared.Outcomes: The primary outcome was to evaluate the impact of this initiative on the frequency of SMART (budesonide‐formoterol without albuterol) prescribing. Prescription frequencies for albuterol and budesonide‐formoterol were also compared separately. Secondary outcomes were Asthma Control Test (ACT) scores and prescribing frequencies among faculty and resident physicians.Results: The total number of eligible patients in the clinic population was 807, and 459 of these patients met the inclusion criteria. There were more females than males, and the mean age was 39. About 24% had a language preference other than English and 22% required an interpreter. The percentage of patients who were prescribed SMART significantly increased from 0.44% to 11.5% (p < 0.001). Budesonide‐formoterol prescriptions increased from 7.4% to 34.6% (p < 0.001). Albuterol metered‐dose inhaler prescriptions decreased from 79.7% to 66.2% (p < 0.001). Prescribing patterns were similar for patients of faculty physicians (n = 258) and resident physicians (n = 196). Only 164 (35.7%) patients had an ACT score in Y1 and Y2, and the mean ACT score was not significantly different between Y1 and Y2 (p = 0.973).Conclusion: A clinical pharmacist‐led SMART asthma prescribing initiative was associated with a significant increase in SMART prescribing, a significant increase in budesonide‐formoterol prescribing, and a significant decrease in albuterol prescribing.
- 1 February 2018
- Published by Elsevier in Complementary Therapies in Clinical Practice
- Vol. 30, 44-49
Reasons for and perceived benefits of utilizing complementary and alternative medicine in U.S. adults with migraines/severe headaches
- 1 February 2018
- Published by Elsevier in Complementary Therapies in Clinical Practice
- Vol. 30, 44-49
Reasons for and perceived benefits of utilizing complementary and alternative medicine in U.S. adults with migraines/severe headaches